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A few single-nucleotide polymorphisms (SNPs) have been identified to be associated with 
cutaneous melanoma (CM) survival though genome-wide association studies, but stringent 
multiple testing corrections required for the hypothesis-free testing may have masked some true 
associations. Using a hypothesis-driven analysis approach, we sought to evaluate associations 
between SNPs in ketone body metabolic pathway genes and CM survival. We comprehensively 
assessed associations between 4,196 (538 genotyped and 3,658 imputed) common SNPs in ketone 
body metabolic pathway genes and CM survival, using a dataset of 858 patients of a case-control 
study from The University of Texas M.D. Anderson Cancer Center as the discovery set and 
another dataset of 409 patients from the Nurses’ Health Study and the Health Professionals 
Follow-up Study as the replication set. There were 95/858 (11.1%) and 48/409 (11.5%) patients 
who died of CM, respectively. We identified two independent SNPs (i.e., PDSS1 rs12254548 G>C 
and SLC16A6 rs71387392 G>A) that were associated with CM survival, with allelic hazards 
ratios of 0.58 (95% confidence interval [CI]=0.44-0.76, P=9.00×10−5) and 1.98 (95% 
CI=1.34-2.94, P=6.30×10−4), respectively. Additionally, associations between genotypes of the 
SNPs and mRNA expression levels of their corresponding genes support the biologic plausibility 
of a role for these two variants in CM tumor progression and survival. Once validated by larger 
studies, PDSS1 rs12254548 and SLC16A6 rs71387392 may be biomarker for CM survival.
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Introduction
Cutaneous melanoma (CM) is the most lethal human skin cancer, accounting for an 
estimated 96,480 new cases and 7,230 deaths in the United States in 2019 1. Though patients 
with a localized CM have a good prognosis, an advanced disease has a very low survival rate 
without aggressive immunotherapeutic treatment 2. Despite advances in accurate prognosis 
for CM, a better understanding of genetic basis for the disease progression will help identify 
new prognostic and therapeutic biomarkers.
The importance of metabolic alterations in melanoma has been recognized 3. For example, 
ketone bodies as an alternative source of metabolic energy, particularly during diminished 
carbohydrate availability, play important roles in metabolic signaling, post-translational 
modification, and inflammation regulation 4,5. Connections between ketone body 
metabolism and cancer progression are accumulating increasingly, offering the possibility of 
precision-guided nutritional therapies 6. Evidence suggests that the ketotic state enhances 
metabolic oxidative stress in cancer cells and thus influences cancer progression 7. Although 
epidemiological associations between cancer and ketogenic diets are debatable, the 
regulation of cellular metabolism via ketogenic diets has been considered as an important 
co-adjuvant therapy in neurological disorders and cancer 8.
Recently, the aberrant expression of ketogenic enzymes have been reported in cancer cells of 
neuroectodermal origin, including melanoma 9. Fenofibrate, a synthetic peroxisome 
proliferator-activated receptor alpha (PPARα) activator, induces beta-hydroxybutyrate 
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production and inhibits proliferation and metastasis in melanoma cells 10. PPARα plays 
important roles in fatty acid oxidation and ketogenesis, and therefore fenofibrate might be 
useful as a complementary adjunct treatment of melanoma 11. Specifically, 3-hydroxy-3-
methylglutaryl-CoA lyase has been shown to induce intracellular accumulation of the ketone 
body acetoacetate, promoting mitogen-activated protein kinase/extracellular-signal regulated 
kinase signaling and growth in an oncogenic BRAF-dependent manner in melanoma cells 12. 
Additionally, the ketone body acetoacetate selectively enhanced the tumor growth of BRAF 
V600E-expressing human melanoma cells in xenograft mice 13. These observations raise the 
question of whether the ketone body metabolism plays a role in melanoma cell bioenergetics 
signaling.
Studies have shown that germline single-nucleotide polymorphisms (SNPs) are associated 
with cancer risk and survival 14,15, suggesting the importance of a genetic basis as a 
molecular mechanism underlying tumor progression. CM is no exception to this paradigm, 
and recent genome-wide association studies (GWASs) have demonstrated several SNPs to be 
associated with susceptibility to CM 16,17. In addition, SNPs may modulate the growth 
characteristics of melanocytic cells 18,19. Given the previous identification of SNPs 
associated with susceptibility to CM, it is likely that identifying genetic variants in 
additional signaling pathway genes will yield novel biomarkers for CM prognosis.
Considering the role of ketogenesis in melanoma growth, it is likely that genetic variants in 
the ketone body metabolic pathway genes could also serve as novel biomarkers of 
prognostic significance for CM patients. To test such a hypothesis, we performed a pathway-
based multigene approach to identify SNPs in genes in the ketone body metabolic pathway 
and examined their associations with survival in CM patients using two published available 
GWAS datasets. It should also be noted that the typically highly stringent GWAS 
significance threshold could be much relaxed for such a targeted pathway-based approach, 
because the number of SNPs to be tested here is greatly reduced.
MATERIALS AND METHODS
Study populations
Patients with a GWAS dataset from The University of Texas MD Anderson Cancer Center 
(MDACC) were included in the discovery study, whereas patients with a GWAS dataset 
from the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) 
of Harvard University were included in the validation study. Detailed descriptions of subject 
selection and data collection for each study have been described elsewhere 16,20, and a 
written informed consent was obtained from all participants after approval by institutional 
review boards at both MD Anderson and Brigham and Women’s Hospital. The MDACC and 
NHS/HPFS datasets included 858 and 409 non-Hispanic white patients with CM, 
respectively. For the MDACC GWAS study, genomic DNA extracted from the whole blood 
was genotyped using the Illumina HumanOmni-Quad_v1_0_B array and the National 
Center for Biotechnology Information Database of Genotypes and Phenotypes (dbGaP; 
http://www.ncbi.nlm.nih.gov/gap), accession number phs000187.v1.p1. Genome-wide 
imputation was then performed using the MACH software program based on the 1000 
Genomes Project, phase I V2 CEU data (March 2010 release) 21. For the NHS/HPFS GWAS 
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study, genotyping was performed using the Illumina HumanHap610 array. Genome-wide 
imputation was also conducted using the MACH software based on the 1000 Genomes 
Project CEU data (phase I v3, March 2012) 22,23.
Gene and SNP extraction
We selected 44 autosomal genes of the ketone body metabolism-related pathway according 
to the databases of Molecular Signatures Database and selected literature (Table S1). In 
brief, genotyped and imputed SNPs within 2-kb up- and down-stream of the genes were 
extracted from the MDACC GWAS dataset following the outlined quality control criteria: 
minor allele frequency (MAF) ≥ 0.05, genotyping success rate > 95%, and Hardy-Weinberg 
equilibrium P value > 1 × 10−5, and from imputation for those SNPs with r2 ≥ 0.8. We 
performed linkage disequilibrium (LD) analysis using HaploView 4.2 according to 373 
Europeans from the 1000 Genomes Project; pairwise r2 ≥ 0.8 was considered in a high LD.
In silico functional analysis
For those SNPs identified in the multivariate analysis as significant, we further performed 
bioinformatics functional prediction using online tools: SNPinfo (http://
snpinfo.niehs.nih.gov), RegulomeDB (http://www.regulomedb.org) and HaploReg (http://
archive.broadinstitute.org/mammals/haploreg/haploreg.php). We then performed an 
expression quantitative trait loci (eQTL) analysis using several data sources: (1) 
lymphoblastoid cell data on 373 European individuals from the 1000 Genomes Project 
(phase I integrated release 3, March 2012, (2) the Genotype Tissue Expression (GTEx) 
project, and (3) primary cutaneous melanoma tissue data from The Cancer Genome Atlas 
(TCGA) database.
Statistical methods
For each GWAS dataset, we performed multivariate Cox proportional hazards regression 
analysis to evaluate associations between the SNPs and CMSS with adjustments of the 
available covariates, using the GenABEL package of R software. CMSS was determined by 
the time from diagnosis to last follow-up or the CM-related death time. In the MDACC 
study, tumor stages were divided into two groups: stages I/II and stages III/IV. Adjustments 
include age, sex, Breslow thickness, tumor stage, ulceration and mitotic rate for the MDACC 
dataset, but only age and sex for the NHS/HPFS dataset. The Bayesian false-discovery 
probability (BFDP) method with a cut-off value of 0.80 was used for multiple testing 
correction, because 87% of the SNPs were imputed and thus in a high LD with other SNPs 
24. The use of BFDP is statistically less stringent than false discovery rate, but it is more 
reasonable for the multiple testing correction for imputed SNPs in this gene-set analysis.
We also assigned a prior probability of 0.1 to detect a hazards ratio (HR) of 2.0 for an 
association with genotypes and alleles of each SNP in the two GWAS datasets. A meta-
analysis was further performed to combine the results of two datasets. A fixed-effects model 
was used because no heterogeneity was found between the two datasets (the Cochran’s Q 
test P-value ˃ 0.100 and the heterogeneity statistic I2 < 50.0%). A Kaplan-Meier curve was 
used to estimate the HRs for CMSS-associated genotypes, and the combination of risk 
genotypes (those associated with increased risk of death) was also used to evaluate the 
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cumulative effects of selected SNPs. For stratified analyses, heterogeneity between 
subgroups was assessed with the χ2-based Q-test and considered significant when P < 0.05. 
A time-dependent receiver operating characteristic (ROC) analysis was performed to 
calculate the area under the curve (AUC) for SNPs and clinical variables using the 
“timeROC” package of R software in the discovery dataset 25. Furthermore, Haploview 
v4.231 and LocusZoom32 were used to construct Manhattan plots and regional association 
plots, respectively 26,27. Correlations between SNPs and their mRNA expression was 
performed by using linear regression analysis 28. Unless otherwise specified, all other 




In the present study, we used a discovery dataset of 858 CM patients from MDACC and a 
validation dataset of 409 CM patients from NHS/HPFS (Table S2). In the MDACC dataset, 
there were slightly more male patients (496, 57.8%) than female patients, ranging in age 
between 17 and 94 years at diagnosis (52.4 ± 14.4 years); 56.8% of these cases were older 
than 50 years. Many more cases were diagnosed with stages I/II (709, 82.6%) than with 
stage III/IV (149, 17.4%). Median follow-up time (81.1 months) ranged between 4.7 and 
175.3 months. In the NHS/HPFS dataset, the age range of CM patients was 34 and 87 years 
at diagnosis (61.1 ± 10.8 years); the majority of the cases were over 50 years old (337, 
82.4%). There were nearly twice as many female patients (271, 66.3%) as male patients 
(138, 33.7%). The median follow-up time was 179.0 months (range 5.0 to 453.0 months). 
During follow-up 95/858 (11.1%) and 48/409 (11.5%) patients died of CM in the MDACC 
dataset and the NHS/HPFS dataset, respectively. We did not adjust for principal components 
in either the discovery or the validation dataset, because no principal components were 
significantly associated with CM survival, indicating the absence of any detectable 
population stratification in either the MDACC or the NHS/HPFS dataset.
Associations between SNPs in the ketone body metabolic pathway genes and CMSS
We present a flow chart of the study design in Figure 1. To assess the associations of 538 
genotyped and 3,658 imputed SNPs of ketone body metabolic pathway genes with CMSS, 
we performed a single locus analysis in the MDACC dataset with adjustments for age, sex, 
tumor stage, Breslow thickness, ulceration, and mitotic rate. A Manhattan plot is provided in 
Figure S1; 211 SNPs were significantly associated with CMSS at P < 0.05, of which 196 
SNPs were still significant after the multiple test correction by BFDP (Table S3). Next we 
assessed the associations between these 196 SNPs and CMSS in the 409 CM patients from 
the NHS/HPFS dataset, of which 173 SNPs were replicated. After Cox regression analysis 
with adjustment for age and sex, 14 SNPs (all imputed) of two genes were validated and 
considered significantly associated with CMSS at P < 0.05, including ten SNPs in PDSS1 
(decaprenyl diphosphate synthase subunit 1) and four SNPs in SLC16A6 (solute carrier 
family 16 member 6) (Table 1). In the subsequent meta-analysis of these two studies, 14 
SNPs in PDSS1 and SLC16A6 genes remained significant in associations with CMSS (Table 
1), and no between-study heterogeneity was observed for these SNPs (Phet > 0.05 for both).
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Genetic variants in the ketone body metabolic pathway genes as independent predictors
We further performed LD analysis of the 14 SNPs in PDSS1 and SLC16A6 and found that 
except for rs2368182, nine other SNPs (i.e., rs12254548, rs1809359, rs3808914, rs7896301, 
rs68159164, rs71483808, rs11015232, rs7904343 and rs1960383) in PDSS1 were in high 
LD (Figure S2a). For SLC16A6, four SNPs were in high LD with each other (i.e., 
rs71387392, rs35924680, rs34080227 and rs12945324) (Figure S2b). Functional prediction 
indicated that five SNPs (i.e., rs1960383, rs12254548, rs3808914, rs7896301 and 
rs11015232) in PDSS1 had a RegulomeDB scores ˂ 4 and two SNPs in SLC16A6 were 
suggested to be located in the 3’-UTR (Table S4). In consideration of P values, LD, and 
predicted functions, we selected rs2368182 and rs12254548 in PDSS1 and rs71387392 in 
SLC16A6 as the independent tagSNPs for further analysis. Then these three SNPs together 
with clinical prognostic variables were included in a multivariate stepwise Cox model from 
the MDACC dataset. As a result, PDSS1 rs12254548 G>C and SLC16A6 rs71387392 G>A 
remained in the model as independent predictors of CMSS (Table S5). For visual 
presentation, these two SNPs are shown in the regional association plots with an expansion 
of 50-kb in the flanks of the corresponding gene region, in which the two selected 
independent representative SNPs are labeled in purple. (Figure S3).
In the MDACC study (with adjustment for covariates where appropriate), a protective effect 
of the PDSS1 rs12254548 C allele (Ptrend = 0.005) but a risk effect of the SLC16A6 
rs71387392 A allele (Ptrend = 0.006) on CM survival were statistically significant in the 
trend test. We also observed similar results for the PDSS1 rs12254548 C allele in the NHS/
HPFS dataset (Ptrend = 0.004), and the combined dataset of MDACC and NHS/HPFS (Ptrend 
< 0.0001) and for the SLC16A6 rs71387392 A allele in the NHS/HPFS dataset (Ptrend = 
0.038) and the combined dataset of MDACC and NHS/HPFS (Ptrend < 0.0001) (Table 2). We 
also present Kaplan-Meier survival curves of the associations with CMSS for risk genotypes 
of PDSS1 rs12254548 and SLC16A6 rs71387392 in Figure 2a-2f.
Survival of CM patients with combined risk genotypes
We combined the risk genotypes of PDSS1 rs12254548 GG and SLC16A6 rs71387392 GA
+AA into one variable as a genetic score to estimate the joint effect of the two SNPs. We 
further categorized all the subjects into three groups: 0, 1, or 2 risk genotype. As shown in 
Table 2, we observed a risk-genotype dose-response effect on CMSS associated with the 
genetic score in the MDACC dataset (Ptrend = 0.0001), the NHS/HPFS dataset (Ptrend = 
0.001), and the combined dataset of MDACC and NHS/HPFS (Ptrend < 0.0001). After that, 
we dichotomized all subjects into the 0 risk genotype group and the 1-2 risk genotypes 
group because of the small number of subjects in some of the subgroups. Compared with the 
0 risk genotype group, the 1-2 risk genotypes group had greater CM-death risk in the 
MDACC dataset (adjusted hazards ratio [HRadj] = 2.18; 95% confidence interval [CI] = 
1.39-3.41, P = 0.0007), the NHS/HPFS dataset (HRadj = 2.84; 95% CI = 1.54-5.24, P = 
0.0009) and the combined dataset of MDACC and NHS/HPFS (HRadj = 2.50; 95% CI = 
1.76-3.56, P < 0.0001). We also used Kaplan-Meier curves to illustrate the associations 
between the number of risk genotypes and CMSS (Figure 2g-2i).
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Stratified analyses for the effect of combined risk genotypes on CMSS
Compared with the 0 risk genotype group, CM patients with 1-2 risk showed a substantially 
increased risk of CM-related death in the presence of clinical variables, which was evident in 
all the subgroups, except for those with tumor cell mitotic rate of ≤ 1/mm2 in the MDACC 
dataset. However, no significant interaction was found among the subgroups (Table S6).
ROC curve and time-dependent AUC
In the ROC curve and time-dependent AUC, we further assessed the risk effect of the two 
independent SNPs in the presence of clinical variables where appropriate for improving the 
classification of 5-year CMSS in the MDACC dataset, the NHS/HPFS dataset and the 
combined dataset of both MDACC and NHS/HPFS. Consistently, the AUC of the five-year 
CMSS improved prediction performance in the above-mentioned three datasets (Figure S4a, 
4c and 4e). The AUC of the 5-year CMSS increased from 85.71% to 86.26% (P = 0.528) 
with the addition of risk genotypes to the model, and this effect was not statistically 
significant in the MDACC dataset. But the AUC of the five-year CMSS in the NHS/HPFS 
dataset significantly increased from 54.05% to 68.76% (P = 0.003) with the addition of risk 
genotypes to the model. We also observed a borderline of P value equals to 0.050 in the 
combined dataset of both MDACC and NHS/HPFS. Through the entire follow-up period, we 
also used the time-dependent AUC curves to assess the ability of risk genotypes in CMSS 
prediction (Figure S4b, 4d and 4f).
Genotype-phenotype correlation analyses
To further explore the potential functions of these two tagSNPs, we performed eQTL to 
evaluate correlations between SNPs and mRNA expression levels in the 1000 Genomes 
Project 22,28. Only the rs12254548 C allele demonstrated a significant association with an 
increased mRNA expression level of PDSS1 in the additive model and the dominant model 
(P = 0.0006 and P = 0.0004, respectively, Figure 3a-3b), while this was not the case for the 
SLC16A6 rs71387392 A allele (data not shown). However, in the TCGA data based on 59 
samples of primary cutaneous melanoma tissue, the SLC16A6 rs71387392 A allele was 
associated with an increased mRNA expression level of SLC16A6 in a dominant model (P = 
0.039, Figure S5). However, no significant associations were observed in the GTEx 
database. We also found the two SNPs (i.e., rs12254548 and rs71387392) to be located in a 
DNase I hypersensitive site, where CpG islands, and histone modification H3K27 
acetylation may regulate activities of enhancer or promoter functions by using experimental 
data from the in ENCODE project. It has also been suggested that rs71387392 is located on 
the Hoxd8 motif by the DNase cluster and transcription factor CHIP-seq data (Figure S6).
Discussion
In the present study, we analyzed associations between SNPs in genes of the ketone body 
metabolism pathway and CMSS using two previously published datasets. We identified two 
SNPs (i.e., PDSS1 rs12254548 and SLC16A6 rs71387392) that were significantly 
associated with CMSS. In subsequent functional prediction analysis, we found that the 
PDSS1 rs12254548 C allele was associated with increased mRNA expression levels of in the 
373 established blood cell lines and that the SLC16A6 rs71387392 A allele was associated 
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with increased mRNA expression levels in primary cutaneous melanoma tissues of 59 
samples from the TCGA dataset.
Ketone bodies have been investigated in cancer cell biology via the fuel metabolism and a 
signaling mechanism 6. Derangements of the ketone body metabolism can affect 
pathophysiological processes in cancer. Identification of such metabolic vulnerability has 
provided opportunities for prognostic and therapeutic strategies in cancer management 29. 
For example, the overexpression of ketolytic enzymes has been reported as a prognostic 
biomarker associated with aggressive phenotypes in prostate cancer and colorectal cancer 
30,31. Venous blood ketone bodies could also predict prognosis of hepatocellular carcinoma 
after transcatheter arterial chemoembolization 32. Importantly, there is also evidence that the 
β-hydroxybutyrate production, stimulated by the peroxisome proliferator-activated receptor 
α agonist fenofibrate, was associated with cell growth arrest and energy stress in murine 
melanoma cells, supporting the importance of the ketone body metabolism in melanoma 
progression 9.
PDSS1 is located on chromosome 10p12.1, encoding an enzyme that elongates the prenyl 
side-chain of ubiquinone, one of the elements in the respiratory chain, and some mutations 
in this gene have been reported. For example, a homozygous missense mutation in PDSS1 
leads to ubiquinone deficiency, which causes an early-onset hearing loss disorder with 
mitochondrial dysfunction 33. Genome-wide gene expression studies have found that PDSS1 
expression levels were upregulated by exposing human osteosarcoma cells to bisphenol A 
analogs 34. A pilot study also suggested that significant upregulation of PDSS1 expression 
levels in whole blood were associated with susceptibility to type 2 diabetes and therapeutic 
response 35. Genetic variants in PDSS1 have also been identified in patients with 
mitochondrial disorders, suggesting its potential role in mitochondrial function 36. Because 
ketone bodies are involved in biological functions, the C allele of PDSS1 rs12254548 is 
associated with increased mRNA expression levels but a better survival, suggesting that 
PDSS1 is likely to be a tumor suppressor in CM progression and prognosis.
SLC16A6, located in chromosome 17q24.2, encodes monocarboxylate transporter 7 
(MCT7), exporting β-hydroxybutyrate from the liver 37, which is important for the lipid 
metabolism. For example, a zebrafish model lacking SLC16A6 developed fatty liver during 
fasting, possibly due to the diversion of acetyl-CoA to lipid synthesis rather than to ketone 
bodies 38. Although a pronounced MCT7 signal was observed in human muscle 39, the 
mechanistic activity of SLC16A6 has not been functionally elucidated. In addition, 
SLC16A6 variants have been significantly associated with risk of breast cancer 40. Another 
report has demonstrated that SLC16A6 expression was up-regulated in paclitaxel- and 
methotrexate- resistant human ovarian cancer cell lines 41. Furthermore, microarray data 
also demonstrated that SLC16A6 expression levels were significantly upregulated in the 
melanoma cell lines exposed to nonsteroidal anti-inflammatory drugs, which suggests the 
possibility of patient selection in clinical settings 42.
The present study has some limitations. First, clinical information on the validation dataset 
from the NHS/HPFS study contains only age and sex, which might explain the difference in 
the AUCs between the two datasets we used. Second, neither of the two datasets had detailed 
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information on administration of a ketogenic diet, history of fatty liver disease, or systemic 
treatments and response, which should have been adjusted for the possible effect on patients’ 
outcomes. Also, further functional investigations should be conducted to provide 
mechanistic insights into these two novel SNPs.
In conclusion, we report some significant associations between CMSS and genetic variants 
in PDSS1 and SLC16A6. CM patients with more numerous risk variant genotypes had 
poorer survival. We believe that these results are likely biologically plausible, since the 
genotype-phenotype correlation demonstrates that PDSS1 expression levels may be 
modulated by rs12254548, although additional investigation is needed to unravel the 
underlying molecular mechanisms. Our data allow us to better understand the role of ketone 
bodies in skin cancer biology and may open up new opportunities for their therapeutic 
application to CM clinical management.
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Figure 1. Research workflow for SNPs in the ketone body metabolic pathway genes.
Abbreviations: AUC, area under curve; BFDP, Bayesian false-discovery probability; CMSS, 
cutaneous melanoma-specific survival; GO, Gene Ontology; GWAS, genome wide 
association study; HWE, Hardy Weinberg equilibrium; KEGG, Kyoto Encyclopedia of 
Genes and Genomes; MAF, minor allele frequency; MDACC, The University of Texas M.D. 
Anderson Cancer Center; NHS, the Nurses’ Health Study; HPFS, the Health Professionals 
Follow-up Study; PDSS1, decaprenyl diphosphate synthase subunit 1; PID, Pathway 
Interaction Database; ROC, receiver operating characteristic; SLC16A6, solute carrier 
family 16 member 6; SNP, single nucleotide polymorphism.
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Figure 2. Selected SNPs and survival prediction.
Kaplan-Meier curves of cutaneous melanoma-specific survival (CMSS) stratified by PDSS1 
rs12254548, assuming a dominant model in (a) the MDACC, (b) the NHS/HPFS and (c) the 
MDACC and NHS/HPFS combined dataset. Kaplan-Meier curves of CMSS stratified by 
SLC16A6 rs71387392 in (d) the MDACC, (e) the NHS/HPFS and (f) the MDACC and 
NHS/HPFS combined dataset. Kaplan-Meier survival curves of the combined risk genotypes 
on CMSS: dichotomized 0 risk genotype group and 1-2 risk genotypes group in (g) the 
MDACC, (h) the NHS/HPFS and (i) the MDACC and NHS/HPFS combined dataset. 
Abbreviations: SNP, single nucleotide polymorphism; CMSS, cutaneous melanoma-specific 
survival; MDACC, The University of Texas M.D. Anderson Cancer Center; NHS, the 
Nurses’ Health Study; HPFS, the Health Professionals Follow-up Study; PDSS1, decaprenyl 
diphosphate synthase subunit 1; SLC16A6, solute carrier family 16 member 6.
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Figure 3. Associations between SNPs and mRNA expression levels of their corresponding genes.
The expression quantitative trait loci (eQTL) analysis from 373 European descendants from 
the 1000 Genomes Project for PDSS1 rs12254548 in the additive model (a) and the 
dominant model (b). Abbreviations: PDSS1, decaprenyl diphosphate synthase subunit 1.
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